Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as high as $0.19. Hemispherx BioPharma shares last traded at $0.19, with a volume of 663,895 shares trading hands.
Hemispherx BioPharma Stock Up 8.4 %
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Featured Stories
- Five stocks we like better than Hemispherx BioPharma
- How to Capture the Benefits of Dividend Increases
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- What is the Nasdaq? Complete Overview with History
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
